Skip to main content Skip to search Skip to main navigation

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Overton is currently deputy director of the White House Domestic Policy Council. Previously, she served as chief policy officer and vice chair of the Center for a Healthy America at AFPI (America First Policy Institute). Before joining AFPI, Overton was a general surgery resident at Johns Hopkins University, where she also obtained a PhD in clinical investigation. 

Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed) said the group supports the nomination. 

“We look forward to continuing our work with FDA under Dr. Overton’s leadership if she is confirmed by the Senate. As a medical doctor with a background in public health, she has a deep understanding of the critical role medical technology plays in lowering cost and improving patient outcomes. The transformative nature of medtech helps ensure that patients are in control of their own health and doctors are empowered to treat patients with the most innovative technologies. It is essential that we continue the progress we have made to ensure that transparency, consistency, and predictability remain the hallmarks of the review process at CDRH.

President Trump wrote on Truth Social: “She is known to take on the HARDEST issues, and bring me solutions that work best for the Country….We need her leadership at the FDA now.”


Source:

RAPS: Trump taps Heidi Overton as next FDA Commissioner

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients.

Read more
Previous
Next